The field of regenerative medicine is rapidly growing with an emphasis on stem cell therapies and the promise of cures for everything from acute injuries to chronic degenerative diseases. The list of indications is expanding as more studies are published to demonstrate safety and efficacy. Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function. The concept is that damaged tissue can be restored by using the body’s own healing mechanism to promote repair. This new branch of medicine may change the course of chronic diseases and standard clinical therapies. However, with any new therapies, this must be approached cautiously and with scientific data to support the treatment. This session will discuss the use of stem cell therapies in degenerative diseases and the challenges of bringing these products to market.
Activities of Bone Marrow Stem and Progenitor Cells! Importance of Cellular Mobilization! Course of Traumatized Tissue! Importance of Neovascularization!
Cells Crucial for Tissue Regeneration! Importance of Paracrine Effect and the Microenvironment! R!elate Basic Science to Clinical Practice
In this presentation I will discuss these emerging technologies and techniques and describe our experience, as the first adipose derived stem cell treatment center in the U.S., in obtaining high yield lipoaspirate tissue sample utilizing the Body-Jet™ (HumanMed, Schwerin, Germany) WAL device as compared to traditional liposuction, syringe based liposuction, and competing technologies. In addition I will discuss our experience utilizing automated SVF processing devices such as the Stem Source™ device by Cytori Inc. (San Diego, CA, USA.) and LipoKit (MediKhan, Seol, Korea) as compared to standardized manual processing methods for the purpose of obtaining graft specimen enhanced with SVF. Flow Cytometry, Growth Kinetics Assay, and Image Analysis data will be presented comparing SVF yield and MSC characterizations as seen when utilizing various techniques for harvesting and processing. A cost effective and clinically feasible solution for the routine storage of SVF enriched adipose tissue for future cosmetic as well as tissue engineering and regenerative applications will also be discussed in detail.
The presentation concerns the use of PRP and Stem cell injections for treatment of musculoskeletal conditions. We wish to take the discussion to the next level by discussing the cutting edge of the cutting edge. Our clinic has made extensive use of Platelet Rich Plasma in conjunction with Bone Marrow Stem Cells (BMAC) and Adipose Stem Cells (SVF) and fat grafts. We have now expanded our practice to use stem cells which until recently were thought to exist in therapy only. All of these components are harvested from the patient, minimally manipulated, and utilized the same day essentially keeping within FDA guidelines.
Adipose derived stem cells are readily available from autologous adipose tissue, and have demonstrated an ability to provide significant potential for repair of damage in multiple animal models. These include models of myocardial infarction, heart failure, hind limb ischemia, neurodegenerative and inflammatory conditions. Early clinical studies have now extended testing of the affects of ASC on patients. Clinical applications of ASCs have begun to show early safety results and promising efficacy potential in patients suffering from a range of diseases. These effects are based on the secretion of trophic and survival factors from these cells, and by their participation in the growth and remodeling of connective tissue and blood vessels. This presentation will highlight some of the clinical trials and case study series in which the author was involved. Dr. Paspaliaris will describe the potential and mechanism of action of ASCs, particularly on diseases such as COPD, osteoarthritis, type 11 diabetes and cardiovascular disease. The results of these studies suggest that ASC could be a valuable therapeutic option in new tissue growth and tissue repair in various clinical settings.
Patients with Advanced Peripheral Vascular Disease usually related to atherosclerotic disease of the arteries of the lower limbs, especially below knees and feet, where it already exists varying degrees of necrosis, little can be done with the endovascular recanalization or surgical, in the absence of distal vessels that can establish an adequate vascular circulation.
This topic explains how to make the distal movement of the foot, blocked, regenerate, back in patent and to reconnect with the proximal vessels, yet permeable and get a fairly quick and efficient relief of the circulation of the lower limb preventing amputation in 80% of patients. Videos and pictures of the procedure and results are displayed.
In the history of cosmetic medicine it has been great interest in autologous fat transfer from the beginning of fat grafting in the 1890s The lipoinjerto is a promising treatment, but currently is limited by the unpredictable results a low rate of graft survival due to partial necrosis. In our experience the use of the assistance of autologous stem cells derived from adipose tissue lipoinjection has ensured satisfactory clinical results without major complications, suggesting that ASC supplements are effective and safe. Protocol and clinical cases demonstrate.
We present case study data obtained from four mildly cognitive impaired Alzheimer’s participants who underwent adult harvested stromal vascular fraction treatment at baseline and then every 90 days for a total 180 days. SLUMS cognitive performance test, SPECT, MRI, and CSF protein analysis (including beta-amyloid and total Tau protein) measurements were obtained at baseline, immediately following treatment, and 90 after treatment ended (Day 216). Improved SLUMS scores were obtained with the first 90 days of the initial treatment. Correspondingly, beta-amyloid and Tau protein were decreased. Improvements were sustained across the group at Day 216.
A growing number of doctors around the world are performing treatments using adult stem cells prepared and administered on the same day of the procedure. However, the number of purified cells is sometimes insufficient to generate the required therapeutic dose. This is because with increasing age of the patient, the number of viable stem cells decreases. Furthermore, the tissue type also affects as the concentration of adult stem cells varies, and often the amount of starting tissue is very limited.
Abstract 1: State of the Cell: Global Trends in Regenerative Medicine. Using data collected from independent survey of stem cells clinics, Audley presents insights into the use of cell as part of the clinical practice of medicine. Working with data collected from the Institute for Global Health and Research, this presentation delves into conditions treated with stem cells, as well as cell types used and how they are processed, and data about average costs of procedures from Latin America to Asia and the Caribbean.
Abstract 2: Effective Patient Acquisition. Using data collected through the development of technologies and over a decade of working in the emerging field of stem cell and regenerative medicine, Audley presents insights into methods of effectively targeted, identifying and engaging qualified patients.
“We treat patients and not diseases”
Regenerative medicine appears not only as a better alternative solution for patients, but as an obligation to recover the exercise of deep medical consultation to allow fully define the problem and the need of the patient. Regenerative medicine is an incentive to recover the value of anamnesis, clinical interview and observation. This work became the conceptual basis of an online software, available to users of this area, which is the world’s first MRA specializes in regenerative medicine. My pleasure to introduce STEMDATA, collecting experience and transforms it into a useful tool for doctors working cell therapy and personalized medicine.
has used several procedures in an effort to restore some post-injury function, including, as discussed here, stem-cell transplantation and, as reviewed later, omental transposition.In preliminary investigations, Bansal has transplanted bone-marrow-derived stem cells into 11 patients with motor-sensory complete injuries (i.e., ASIA-A) sustained at least a year earlier from contusion or laceration. Nine possessed cervical injuries and two thoracic injuries, and all except one were men. Although most were younger than 30, age ranged from 20 to 52.
The stem cells were obtained by aspirating ~120 milliliters of bone marrow from the patient’s iliac crest, a bone-marrow abundant area of the pelvis bone, and then obtaining a stem-cell rich concentrate by centrifugation. To maintain their fundamental nature, as well as the presence of regenerative-enhancing growth factors, no further physical, chemical, or biological processing of the cells was carried out before transplantation.
THE CURRENT USE OF ADIPOSE DERIVED STEM CELLS and BONE Marrow STEM CELLS CONSTITUTES A THERAPEUTIC APPROACH WHICH DAY BY DAY GAINS GROUND IN MANY MEDICAL APPLICATIONS, THROUGH various specialties.
HOWEVER, FOR CERTAIN CONDITIONS WE PHYSICIANS HAVE TO ADOPT OTHER RESOURCES IN SUPPORT OF THERAPEUTIC USE OF STEM CELLS.